Physician
Obstetrics & Gynecology
Dr. David Portman, PHARMD
|
|
Give Review
David Portman PHARMD practices Obstetrics & Gynecology. He graduated from The Ohio State University College of Medicine. He over the years received 1 awards: "Fellow (FACOG)". David Portman, PHARMD is also published. He has 20 publications published. The lastest publication: "Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinar...' David Portman PHARMD accepts Medicare.
Publications
- Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinar...
- One-year treatment persistence with local estrogen therapy in postmenopausal women diagnosed as having vaginal atrophy.
- Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy.
- Self-reported and verified compliance in a phase 3 clinical trial of a novel low-dose contraceptive patch and pill.
- New contraceptive patch wearability assessed by investigators and participants in a randomized phase 3 study.
- Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
- Genitourinary Syndrome of Menopause: New Terminology for Vulvovaginal Atrophy from the International Society for the Study of Women's Sexual Health and The North Ameri...
- Safety Profile of Paroxetine 7.5 mg in Women With Moderate-to-Severe Vasomotor Symptoms.
- Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women.
- Low-dose levonorgestrel and ethinyl estradiol patch and pill: a randomized controlled trial.
- Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated with menopause.
- Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel/ethinyl estradiol combined oral contraceptive.
- Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials.
- Adding low-dose estrogen to the hormone-free interval: impact on bleeding patterns in users of a 91-day extended regimen oral contraceptive.
- A retrospective managed care claims data analysis of medication adherence to vaginal estrogen therapy: implications for clinical practice.
- A randomized, double-blind, placebo-controlled, multicenter study that assessed the endometrial effects of norethindrone acetate plus ethinyl estradiol versus ethinyl ...
- Menopause Pharmacotherapeutic Development--CBI''s second annual conference.
- Long-term safety of an extended-cycle oral contraceptive (Seasonale): a 2-year multicenter open-label extension trial.
- Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol.
Doctors Specialties
- Pharmacy Clinician Services
- Obstetrics
- Gynecology
Accepted Insurances
Awards
- Fellow (FACOG)
Education
-
Ohio State University Hospital -
The Ohio State University College of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. William C. Dundore Jr., MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael V. England, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Julian C. Tolentino, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Emily R. Dryden, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Philip M. Lenko, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ashley M. Craig, PHARMD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brandi K. Lumley, PHARMD |